NK-Cell Receptor Repertoire in Chronic Myeloid Leukemia

Tamara Vangelevna Chitanava, R.A. Vlasik, L.O. Khordzhasov, A. Ataman, N.S. Luchkina, A.Yu. Aronov, I.D. Matvienko, N.T. Siordiya, O.V. Kulemina, N.S. Lazorko, E.I. Sbityakova, N.A. Shnalieva, E.N. Tochenaya, J.A. Alekseeva, P.A. Butylin, S.V. Smirnov, Yu. A. Zaritskii, Yu.P. Martinova, E.G. Lomaia,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-2-152-161

BACKGROUND. Escape of leukemia cells from immune surveillance appears to be one of the most relevant areas in the study of resistance mechanisms in chronic myeloid leukemia (CML).

AIM. To study the characteristics of the NK-cell immune response in patients with chronic phase (CP) CML on third-line therapy with tyrosine kinase inhibitors (TKIs) of the second generation.

MATERIALS & METHODS. The study enrolled 40 CML CP patients receiving third-line therapy at the VA Almazov National Medical Research Center. The control group consisted of 20 healthy subjects (HS). The quantitative characteristics of NK- and TNK-cells as well as the expression of activating and inhibitory receptors on NK-cells were assessed using flow cytometry. KIR (Killer cell Immunoglobulin-like Receptors) haplotypes were analyzed by PCR and electrophoresis of PCR amplification products.

RESULTS. Irrespective of treatment response, CML patients showed no significant differences regarding either the quantitative characteristics of NK- and TNK-cells or activating and inhibitory receptors on NK-cells. However, in the quantitative characteristics of inhibitory KIR alleles as well as in the expression of two activating KIR alleles (KIR2DS4 and KIR3DS1), significant differences were identified in HS vs. CML patients (p < 0.05). At the same time, the expression rate was similar in the groups with optimal response and therapy resistance (p = 0.25). There were also no significant differences in the rate of KIR haplotypes in HS and two groups of patients. In most CML patients as well as in HS, Bx haplotype of KIR was identified. The percentage of deaths was higher in the group with A haplotype (4/9; 45 %) vs. Bx haplotype (4/31; 13 %) (p = 0.008). The median progression-free survival (PFS) in the A haplotype subgroup was 76 (range 24–162) months vs. 69 (range 3–179) months in the Bx haplotype subgroup; the median overall survival (OS) was 69 (18–179) months vs. 76 (24–159) months, respectively.

CONCLUSION. No significant differences were revealed in the expression of activating and inhibitory receptors on NK-cells in both groups of patients with response to TKI third-line therapy and therapy resistance compared to HS. This study demonstrated that NK-cell immune response had no effect on complete cytogenetic response. The results of the study suggest that the assessment of NK-cell immune response and KIR haplotypes cannot be regarded as a valuable tool for predicting the treatment efficacy in CML CP patients. However, due to heterogeneity of the groups under this study, further research is necessary to understand the prognostic value of KIR haplotypes in achieving response to therapy as well as their effect on OS and PFS.

  • Tamara Vangelevna Chitanava Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040 ; VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0002-9390-9154 (unauthenticated)
  • R.A. Vlasik VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 ; Saint-Petersburg Pasteur Research Institute for Epidemiology and Microbiology, 14 Mira ul., Saint Petersburg, Russian Federation, 197101 https://orcid.org/0000-0003-1843-6964 (unauthenticated)
  • L.O. Khordzhasov VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 ; Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
  • A. Ataman VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • N.S. Luchkina VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • A.Yu. Aronov VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • I.D. Matvienko VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0002-3655-1707 (unauthenticated)
  • N.T. Siordiya VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0001-7081-4999 (unauthenticated)
  • O.V. Kulemina VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0002-0867-3547 (unauthenticated)
  • N.S. Lazorko VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0002-7199-3252 (unauthenticated)
  • E.I. Sbityakova VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0009-0007-9943-4093 (unauthenticated)
  • N.A. Shnalieva VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0003-2876-0434 (unauthenticated)
  • E.N. Tochenaya VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • J.A. Alekseeva VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0003-4453-5616 (unauthenticated)
  • P.A. Butylin VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • S.V. Smirnov VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • Yu. A. Zaritskii VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
  • Yu.P. Martinova Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040 https://orcid.org/0009-0006-2045-7026 (unauthenticated)
  • E.G. Lomaia VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341 https://orcid.org/0000-0003-3290-7961 (unauthenticated)
  1. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):1126. doi: 10.1182/blood.V114.22.1126.1126. DOI: https://doi.org/10.1182/blood.V114.22.1126.1126
  2. Hehlmann R, Lauseker M, Saussele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–406. doi: 10.1038/leu.2017.253. DOI: https://doi.org/10.1038/leu.2017.253
  3. Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361–8. doi: 10.1182/blood-2009-05-221531. DOI: https://doi.org/10.1182/blood-2009-05-221531
  4. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010;24(7):1299–301. doi: 10.1038/leu.2010.110. DOI: https://doi.org/10.1038/leu.2010.110
  5. Ribeiro BF, Miranda EC, Albuquerque DM, et al. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors—a single center experience. Clinics (Sao Paulo). 2015;70(8):550–5. doi: 10.6061/clinics/2015(08)04. DOI: https://doi.org/10.6061/clinics/2015(08)04
  6. Лазорко Н.С., Ломаиа Е.Г., Романова Е.Г. и др. Ингибиторы тирозинкиназ второго поколения и их токсичность у больных в хронической фазе хронического миелолейкоза. Клиническая онкогематология. 2015;8(3):302–8. doi: 10.21320/2500-2139-2015-8-3-302-308. [Lazorko N.S., Lomaia E.G., Romanova E.G., et al. Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia. Clinical oncohematology. 2015;8(3):302–8. doi: 10.21320/2500-2139-2015-8-3-302-308. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2015-8-3-302-308
  7. Ali S, Sergeant R, O’Brien SG, et al. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood. 2012;120(3):697–8. doi: 10.1182/blood-2012-04-421016. DOI: https://doi.org/10.1182/blood-2012-04-421016
  8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–9. doi: 10.1126/science.1198687. DOI: https://doi.org/10.1126/science.1198687
  9. Chiorean EG, Dylla SJ, Olsen K, et al. BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). Blood. 2003;101(9):3527–33. doi: 10.1182/blood-2002-04-1172. DOI: https://doi.org/10.1182/blood-2002-04-1172
  10. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6):1935–47. doi: 10.1182/blood-2002-02-0350. DOI: https://doi.org/10.1182/blood-2002-02-0350
  11. Binotto G, Frison L, Boscaro E, et al. Comparative analysis of NK receptor and T-cell receptor repertoires in patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Blood. 2014;124(21):5508. doi: 10.1182/blood.V124.21.5508.5508. DOI: https://doi.org/10.1182/blood.V124.21.5508.5508
  12. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. doi: 10.1126/science.1203486. DOI: https://doi.org/10.1126/science.1203486
  13. Rossignol A, Levescot A, Jacomet F, et al. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol. 2012;42(7):1870–5. doi: 10.1002/eji.201142043. DOI: https://doi.org/10.1002/eji.201142043
  14. Jacomet F, Cayssials E, Barbarin A, et al. The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia. Front Immunol. 2017;7:688. doi: 10.3389/fimmu.2016.00688. DOI: https://doi.org/10.3389/fimmu.2016.00688
  15. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. doi: 10.1182/blood-2013-05-501569. DOI: https://doi.org/10.1182/blood-2013-05-501569
  16. Трушина Э.Н., Мустафина О.К., Алексеева И.А. и др. Показатели клеточного иммунитета у условно здоровых лиц в зависимости от возраста и индекса массы тела. Вопросы питания. 2016;85(S2):247. [Trushina E.N., Mustafina O.K., Alekseeva I.A., et al. Cellular immunity indicators in relatively healthy subjects depending on age and body mass index. Voprosy pitaniya. 2016;85(S2):247. (In Russ)]
  17. Chidrawar SM, Khan N, Chan YL, et al. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing. 2006;3:10. doi: 10.1186/1742-4933-3-10. DOI: https://doi.org/10.1186/1742-4933-3-10
  18. Общероссийский национальный союз «Ассоциация онкологов России», Некоммерческое партнерство содействия развитию гематологии и трансплантологии костного мозга «Национальное гематологическое общество». Клинические рекомендации «Хронический миелолейкоз». М., 2020. (электронный документ) Доступно по: https://oncology-association.ru/wp-content/uploads/2020/09/hronicheskij_mielolejkoz.pdf. Ссылка активна на 08.12.2025. [All-Russia National Society “Russian Oncology Association”, Non-Commercial Partnership for Hematology and Bone Marrow Transplantation Support “National Society of Hematologists”. Clinical Guidelines “Chronic Myeloid Leukemia”. Moscow; 2020. (Internet) Available from: https://oncology-association.ru/wp-content/uploads/2020/09/hronicheskij_mielolejkoz.pdf. Accessed 08.12.2025. (In Russ)]
  19. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. doi: 10.1038/s41375-020-0776-2. DOI: https://doi.org/10.1038/s41375-020-0776-2
  20. Kotsakis A, Harasymczuk M, Schilling B, et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012;381(1–2):14–22. doi: 10.1016/j.jim.2012.04.004. DOI: https://doi.org/10.1016/j.jim.2012.04.004
  21. Szmania S, Lapteva N, Garg TK, et al. Expanded natural killer (NK) cells for immunotherapy: fresh and made to order. Blood. 2012;120(21):1912. doi: 10.1182/blood.V120.21.1912.1912. DOI: https://doi.org/10.1182/blood.V120.21.1912.1912
  22. Bayigga L, Nabatanzi R, Sekiziyivu PN, et al. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. BMC Immunol. 2014;15:2. doi: 10.1186/1471-2172-15-2. DOI: https://doi.org/10.1186/1471-2172-15-2
  23. Frutoso M, Mair F, Prlic M. OMIP-070: NKp46-Based 27-Color Phenotyping to Define Natural Killer Cells Isolated From Human Tumor Tissues. Cytometry A. 2020;97(10):1052–6. doi: 10.1002/cyto.a.24230 DOI: https://doi.org/10.1002/cyto.a.24230
  24. Björklund AT, Schaffer M, Fauriat C, et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood. 2010;115(13):2686–94. doi: 10.1182/blood-2009-07-229740. DOI: https://doi.org/10.1182/blood-2009-07-229740
  25. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology. 2010;129(1):8–19. doi: 10.1111/j.1365-2567.2009.03208.x. DOI: https://doi.org/10.1111/j.1365-2567.2009.03208.x
  26. Almeida JS, Couceiro P, López-Sejas N, et al. NKT-like (CD3+ CD56+) cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Front Immunol. 2019;10:2493. doi: 10.3389/fimmu.2019.02493. DOI: https://doi.org/10.3389/fimmu.2019.02493
  27. La Nasa G, Caocci G, Littera R, et al. Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 2013;41(5):424–31. doi: 10.1016/j.exphem.2013.01.008. DOI: https://doi.org/10.1016/j.exphem.2013.01.008
  28. Ureshino H, Shindo T, Kojima H, et al. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res. 2018;6(6):745–74. doi: 10.1158/2326-6066.CIR-17-0462. DOI: https://doi.org/10.1158/2326-6066.CIR-17-0462
  29. Читанава Т.В. Факторы прогноза эффективности терапии ингибиторами тирозинкиназ второго поколения в третьей линии терапии хронической фазы хронического миелоидного лейкоза: Автореф. дис. … канд. мед. наук. СПб., 2025. [Chitanava T.V. Faktory prognoza effektivnosti terapii ingibitorami tirozinkinaz vtorogo pokoleniya v tretei linii terapii khronicheskoi fazy khronicheskogo mieloidnogo leikoza. (Prognostic factors of the efficacy of third-line therapy with 2nd generation tyrosine kinase inhibitors in patients with chronic phase of chronic myeloid leukemia.) (dissertation) Saint-Petersburg; 2025. (In Russ)]
  30. Kreutzman A, Jaatinen T, Greco D, et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol. 2012;40(11):906–13.e1. doi: 10.1016/j.exphem.2012.07.007. DOI: https://doi.org/10.1016/j.exphem.2012.07.007
  31. Vigón L, Luna A, Galán M, et al. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission. J Clin Med. 2020;10(1):42. doi: 10.3390/jcm10010042. DOI: https://doi.org/10.3390/jcm10010042
  32. Ureshino H, Ueda Y, Fujisawa S, et al. KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study. Blood Neoplasia. 2024;1(1):100001. doi: 10.1016/j.bneo.2024.100001. DOI: https://doi.org/10.1016/j.bneo.2024.100001

Keywords:

NK-cells, activating receptors, inhibitory receptors, KIR haplotypes, chronic myeloid leukemia

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Tamara Vangelevna Chitanava, MD, PhD, Clinical Oncology Dispensary No. 1, 146 Dimitrova ul., Krasnodar, Russian Federation, 350040, VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341, e-mail: chitanava.tamara@yandex.ru
2026-2

Downloads

Published

01.04.2026

Issue

Vol. 19 No. 2 (2026)
MYELOID TUMORS

How to Cite

Chitanava T.V., Vlasik R.A., Khordzhasov L.O., et al. NK-Cell Receptor Repertoire in Chronic Myeloid Leukemia. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(2):152–161. doi:10.21320/2500-2139-2026-19-2-152-161.

Most read articles by the same author(s)

1 2 3 > >>